Portal de Periódicos da CAPES

Efficacy and Adverse Effects of Oral Iron Supplements

1999; Wiley; Volume: 12; Issue: 4 Linguagem: Inglês

10.1046/j.1525-139x.1999.99034.x

1525-139X

David B. Van Wyck,

Hemoglobinopathies and Related Disorders

Seminars in DialysisVolume 12, Issue 4 p. 235-236 Efficacy and Adverse Effects of Oral Iron Supplements David B. Van Wyck, David B. Van Wyck University of Arizona College of Medicine, Tucson, ArizonaSearch for more papers by this author David B. Van Wyck, David B. Van Wyck University of Arizona College of Medicine, Tucson, ArizonaSearch for more papers by this author First published: 05 January 2002 https://doi.org/10.1046/j.1525-139X.1999.99034.xCitations: 2 David B. Van Wyck MD Associate Professor of Medicine Department of Medicine, P.O. Box 245099, Arizona Health Sciences Center, Tucson, AZ 85724 Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL No abstract is available for this article. References 1 Baynes RD & Bothwell TH: Iron deficiency. Annu Rev Nutr 10: 133 148, 1990 2 Crosby WH: The rationale for treating iron deficiency. Arch Intern Med 144: 471 472, 1984 3 Cook JD & Skikne BS: Intestinal regulation of body iron. Blood Rev 1: 267 272, 1987 4 National Kidney Foundation–Dialysis Outcomes Quality Initiative: Clinical practice guidelines for the treatment of anemia of chronic renal failure. Am J Kidney Dis 30(Suppl 3): S192 S240, 1997 5 Fishbane S, Frei GL, Maesaka JK: Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. Am J Kidney Dis 26: 41 46, 1995 6 Sunder-Plassmann G & Hörl WH: Importance of iron supply for erythropoietin therapy. Nephrol Dial Transplant 10: 2070 2076, 1995 7 Wingard RL, Parker RA, Ismail N, et al.: Efficacy of oral iron therapy in patients receiving recombinant human erythropoietin. Am J Kidney Dis 25: 433 439, 1995 8 MacDougall IC, Tucker B, Thompson J, et al.: A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int 50: 1694 1699, 1996 9 Andrews N & Levy J: Iron is hot: An update on the pathophysiology of hemochromatosis. Blood 92: 1845 1851, 1998 10 Middleton EJ, Nagy E, Morrison AB: Studies on the absorption of orally administered iron from sustained-release preparations. N Engl J Med 274: 136 139, 1966 11 Heinrich HC, Fischer R, Gabbe EE, et al.: Bioavailability of trivalent iron in oral iron (III)-hydroxide-dextrin (= polymaltose) complex in man. Klin Wochenschr 61: 103 110, 1983 12 Harju E: Clinical pharmacokinetics of iron preparations. Clin Pharmacokinet 17: 69 89, 1989 13 Tinawi M, Martin KJ, Bastani B: Oral iron absorption test in patients on CAPD. Comparison of ferrous sulfate and polysaccharide ferric complex. Nephron 74: 291 294, 1996 14 Bonnar J, Goldberg A, Smith JA: Do pregnant women take their iron? Lancet 1: 457 458, 1969 15 O'Neill-Cutting MA & Crosby WH: Blocking of iron absorption by a preliminary oral dose of iron. Arch Intern Med 147: 489 491, 1987 16 Hallberg L, Brune M, Rossander L: Iron absorption in man: Ascorbic acid and dose-dependent inhibition by phytate. Am J Clin Nutr 49: 140 144, 1989 17 Bendich A & Cohen M: Ascorbic acid safety: Analysis of factors affecting iron absorption. Toxicol Lett 51: 189 201, 1990 18 Hunt JR, Mullen LM, Lykken GI, et al.: Ascorbic acid: Effect on ongoing iron absorption and status in iron-depleted young women. Am J Clin Nutr 51: 649 655, 1990 Citing Literature Volume12, Issue4August 1999Pages 235-236 ReferencesRelatedInformation